These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24599141)

  • 21. Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: comparison with milrinone.
    Fujino K; Sperelakis N; Solaro RJ
    Circ Res; 1988 Nov; 63(5):911-22. PubMed ID: 2846200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac Ca2+ signaling and Ca2+ sensitizers.
    Endoh M
    Circ J; 2008 Dec; 72(12):1915-25. PubMed ID: 18981594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure.
    Ohte N; Cheng CP; Suzuki M; Little WC
    J Pharmacol Exp Ther; 1997 Jul; 282(1):23-31. PubMed ID: 9223536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.
    Udvary E; Papp JG; Végh A
    Br J Pharmacol; 1995 Feb; 114(3):656-61. PubMed ID: 7735692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium.
    Böhm M; Morano I; Pieske B; Rüegg JC; Wankerl M; Zimmermann R; Erdmann E
    Circ Res; 1991 Mar; 68(3):689-701. PubMed ID: 1660359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors.
    Holubarsch C
    Cardiology; 1997; 88 Suppl 2():12-20. PubMed ID: 9142431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension.
    Morita T; Nakamura K; Osuga T; Kawamoto S; Miki S; Sasaoka K; Takiguchi M
    J Vet Cardiol; 2020 Dec; 32():16-27. PubMed ID: 33080489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
    Chu KM; Shieh SM; Hu OY
    Clin Pharmacol Ther; 1995 Jun; 57(6):610-21. PubMed ID: 7781260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
    Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
    J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of pimobendan on myocardial mechanical function and metabolism in dogs: comparison with dobutamine.
    Ichihara K; Abiko Y
    J Pharm Pharmacol; 1991 Aug; 43(8):583-8. PubMed ID: 1681075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation on SCH00013, a novel cardiotonic agent with Ca++ sensitizing action. 4th communication: influence on experimentally induced ventricular arrhythmia in dogs.
    Yoshimura A; Yoshioka K; Hino M; Sugawara H; Sakato M; Endoh M
    Arzneimittelforschung; 1999 May; 49(5):420-6. PubMed ID: 10367104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
    Sarcinella F; Neves J; Maddox TW; Hodgkiss-Geere HM; Bode EF; Dukes-McEwan J
    Open Vet J; 2020 Jan; 9(4):375-383. PubMed ID: 32042661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the positive inotropic agents milrinone and pimobendan on the development of lethal ischemic arrhythmias in conscious dogs with recent myocardial infarction.
    Lynch JJ; Uprichard AC; Frye JW; Driscoll EM; Kitzen JM; Lucchesi BR
    J Cardiovasc Pharmacol; 1989 Oct; 14(4):585-97. PubMed ID: 2478772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac profile of EGIS-9377, a novel cardiotonic agent as a Ca2+ sensitizer with bradycardiac activity.
    Hattori Y; Ishitani T; Tomita F; Gando S; Yokoshiki H; Azuma M; Kemmotsu O; Kanno M
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):585-90. PubMed ID: 10598798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
    Lake-Bakaar GA; Singh MK; Kass PH; Griffiths LG
    J Vet Cardiol; 2015 Jun; 17(2):120-8. PubMed ID: 26007710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inotropic agents with calcium-sensitizing properties: clinical and hemodynamic effects of pimobendan.
    Kubo SH
    Coron Artery Dis; 1994 Feb; 5(2):119-26. PubMed ID: 8180743
    [No Abstract]   [Full Text] [Related]  

  • 38. Use of pimobendan in the management of heart failure.
    Fuentes VL
    Vet Clin North Am Small Anim Pract; 2004 Sep; 34(5):1145-55. PubMed ID: 15325474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The positive inotropic effect of pimobendan involves stereospecific increases in the calcium sensitivity of cardiac myofilaments.
    Solaro RJ; Fujino K; Sperelakis N
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S7-12. PubMed ID: 2478795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
    Katz SD; Kubo SH; Jessup M; Brozena S; Troha JM; Wahl J; Cohn JN; Sonnenblick EH; LeJemtel TH
    Am Heart J; 1992 Jan; 123(1):95-103. PubMed ID: 1729854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.